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
'#( &%)* $To investigate the effect of mobile phone applications on glycemic 
control (HbA1c) in the self 9management of diabetes. 
 $ & $)++, %'$Relevant studies that were published 
between 1996 to June 1st, 2015 were searched from five databases: Medline, 
CINAHL, The Cochrane Library, Web of Science, and EMBASE. Randomized 
controlled trials that evaluated diabetes apps were included. We conducted a 
systematic review with meta9analysis and GRADE of the evidence. 
 $-.%$1360 participants from 14 studies were included and quality assessed. 
Whilst there may have been clinical diversity, all type 2 diabetes studies reported a 
reduction in HbA1c. The mean reduction in participants using an app compared to 
control was 0.49% (95% Cl 0.30%90.68%;=10%), with a moderate GRADE of 
evidence. Subgroup analyses indicated that younger patients were more likely to 
benefit from the use of diabetes apps and the effect size was enhanced with 
healthcare professional feedback. There was inadequate data to describe the 
effectiveness of apps for type 1 diabetes. 
&'+&.-$)'+$Apps may be an effective component to help control HbA1c, and 
could be considered as an adjuvant intervention to the standard self9management for 
patients with type 2 diabetes. Given the reported clinical effect, the access and 
nominal cost of this technology, it is likely to be effective at the population level. The 
functionality and use of this technology needs to be standardized, but policy and 
guidance is anticipated to improve diabetes self9management care. 

/&01234
/&0,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 There is a moderate level of evidence that the self9management of type 2 
diabetes is improved by using smart phone applications to reduce HbA1c 
 
 Apps may offer a clinically effective component in the self9management of 
type 2 diabetes 
 
 Younger users were associated with the largest reduction in HbA1c 
 
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The number of diabetes patients globally is expected to rise to over 500 million by 
2030 (1), there is an urgent need for an improved self9management suite of 
interventions. For self9management to be effective it needs to be structured and cost 
effective (2), and be widely accessible across all health economies, including the 
developing world (2). 
As a newly emerging technology, diabetes mobile phone applications (hereafter 
referred to as diabetes apps) are a promising tool for self9management. We define 
diabetes apps as mobile phone software that accepts data (transmitted or manual 
entry), and provides feedback to patients on improved management (automated or 
by health care profession [HCP]). This technology combines the functions of the 
mobile phone, wireless network for data transmission and sometimes HCPs for 
providing feedback. Due to its ubiquitous, low cost, interactive, and dynamic health 
promotion, there is potential for diabetes apps to provide an effective intervention in 
diabetes self9care. 
In terms of diabetes self9management, numerous studies have proven the 
effectiveness of other telemedicine technologies, such as short message service (3), 
computer9based interventions (4), and web9based interventions (3; 5). Compared 
with these telemedicine interventions, diabetes apps are advantageous in that they 
are global, cheaper, convenient, and more interactive. There is however, current 
uncertainty on the clinical effectiveness of diabetes apps in diabetes self9
management (699).  
 
, %'$
 
0

The PRISMA statement and checklist was followed. Five electronic databases were 
searched (Medline, CINAHL, The Cochrane Library, Web of Science, and EMBASE) 
for studies published between January 1st, 1996 to  June 1st, 2015. Included studies’ 
references were hand searched to identify any additional articles. The following 
terms and medical subject headings (MeSH) were used during the search: (mobile 
OR mHealth OR cell phone OR MeSH “Cellular Phone” OR MeSH “Smartphone” OR 
app OR MeSH “Mobile Applications”) AND (MeSH “Diabetes Mellitus” OR diabete* 
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OR T2DM OR T1DM OR IDDM OR NIDDM).  
 
)070
The inclusion criteria were: the participants were over 18 years old and had type 1 or 
type 2 diabetes; the studies were randomized controlled trials (RCTs); the control 
group in the study received usual diabetes care without any telehealth programs; 
baseline and follow9up mean for HbA1c were reported (or could be calculated).; 
Exclusion criteria were: simulated or self9reported HbA1c data; computer or other 
mobile terminal9based diabetes apps; diabetes apps were exclusively designed for 
HCPs; and diabetes apps were exclusively designed for providing general education, 
or allowing communication between patients and HCPs.  
 
Two reviewers (CH, TF) searched the literature and assessed the studies 
independently. Any disagreements were resolved through discussion with a third 
reviewer (BC). No language restrictions were applied.  
 
7 
Participant demographics, study design considerations and context were extracted 
from the included studies. Two reviewers independently carried out the data 
extraction (CH, TF). Study authors were contacted to provide additional data, and 
missing standard deviations were estimated by calculation (10). 
 
80 
The quality assessment was conducted by two reviewers independently (CH, TF), 
using the quality rating tool proposed by the US Preventive Service Task Force (11).  
Seven criteria were used to assess quality: baseline comparability of the groups; the 
maintenance of comparability of the groups; differential or high loss to follow9up; 
reliable  and valid measurement; clear definition of the intervention; consideration of 
important outcomes; and an intention9to9treat analysis. The quality of each study was 
graded as Good, Fair, or Poor. To be rated as good studies needed to meet all the 
criteria. A study was rated as poor if one (or more) domain was assessed as having 
a serious flaw. Studies that met some but not all of the criteria was rated as fair 
quality.  
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Changes in HbA1c, or HbA1c at follow9up were compared between groups using a 
mean difference, and were presented with an associated 95% confidence interval 
(95% CI). When studies investigated interventions and contexts that were both 
deemed clinically similar, and free from statistical heterogeneity, pooling was carried 
using an inverse variance random effects model (12). Meta9analyses were 
conducted using the Comprehensive Meta9Analysis Software (version 2.2). The level 
of evidence was applied to the GRADE criteria and reported. 
 
00	
Heterogeneity was assessed and quantified using the  statistic. When substantial 
heterogeneity was found (2>50%), further exploration using subgroup analysis was 
undertaken. For type 2 diabetes studies, subgroup analyses were: follow9up duration 
(less than six months, versus more than six months); length of time with diabetes 
(less than nine years, versus more than nine years); age of participants (mean age 
less than 55 years old, versus more than 55 years old); number of self9monitoring 
tasks supported by the diabetes apps (up to three, versus greater than three); and 
types of feedback provided. No type 1 diabetes subgroup analyses were performed 
due to the small number of studies.  
 
$	0 
Additional analyses were carried out on studies with: good or fair quality; complete 
information; and studies with a baseline HbA1c level less than 9.0%. A funnel plot 
was used to visually inspect publication bias where 10 or more studies were pooled.  
 
0
)00
Searches identified 5209 articles, 4238 were screened after removing duplicate 
records and 4178 were excluded. Sixty studies were eligible for full text review and 
42 were excluded (Figure 1) resulting in 14 included studies. Four studies examined 
type 1 diabetes and 10 studies examined type 2 diabetes. 

&

0090
In the 14 studies, there were 1360 participants, 509 and 851 with type 1 and type 2 
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diabetes respectively (Online Table 1). In the type 1 diabetes studies, the mean age 
of participants ranged from 34 (13) to 36 years old (14), and the mean duration of 
diabetes ranged from 16 (13915) to 19 years (16). Two studies were undertaken in 
Europe (13; 14), one in Australia (16) and one was multinational (15). In the type 2 
diabetes studies, the mean age of the participants was much higher, ranging from 51 
(17) to 62 years old (18) and the mean duration of diabetes ranged from five (19) to 
13 years (20) from six studies. Four studies were undertaken in Europe (18; 20922), 
three in the USA (17; 23; 24), two in Asia (19; 25) and one in Africa (26).  
 
One type 1 diabetes study was assessed as good quality (14), two were rated as fair 
(13; 15), and one was rated as poor (16), for further details see Online Table 2. For 
type 2 diabetes studies, one was rated as good quality (21), six were rated as fair 
(17919; 22; 24; 25) and three were rated as poor (20; 23; 26) (Online Table 2). 

)+&.- :)-   
		0
00
Twelve diabetes apps were identified and examined in this review, with six domains 
of functionality (Online Table 3), details of the feedback provided by each can be 
seen in Online Table 4 
 
%			
Three apps were used for participants with type 1 diabetes and aimed to help 
patients to calculate the most appropriate insulin bolus, on the basis of patient blood 
glucose levels, food intake and physical activity. Data for all three apps were 
manually entered. One study reported that there was little impact of the app on the 
total time spent on face9to9face or telephone follow9up and concluded that the 
software did not require more time for patients to manage their diabetes (13). A 
further study estimated the average cost to patients and educators time was £38 per 
patient, attributed to the app over a 9 month period (16). HCP feedback was 
provided in all apps, with a frequency ranging from every week to every three weeks 
(Online Table 4). 
 
%	2		
Nine apps were used for participants with type 2 diabetes. The apps were designed 
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to improve patient self9management, by providing personalized feedback on self9
monitoring data, such as blood glucose, food intake, and physical activity. In eight of 
the apps, BG was automatically transferred and other data manually entered., with 
one exception where BP, body weight and pedometer was also automatically 
transferred (25),.Quinn et al. (17) reported that the app was associated with shorter 
consultation times. Among seven apps with HCP feedback, three provided feedback 
when needed (eg patient data were considered abnormal). In the other apps, the 
frequency of feedback ranged from once a week to once every three months (Online 
Table 4).

 
		
%	
There were mixed results from the type 1 diabetes studies. Two studies (14; 15) 
found no difference between the intervention group and the control group and two 
studies (13; 16) reported statistically significant results that favored the apps. There 
was a statistically insignificant difference in HbA1c between the apps and control 
group of 90.36% (95% Cl 90.87% to 0.14%, P = 0.16,  = 87%; Figure 2). No 
subgroup analyses were reported.  
 
)+&.- :)- 2  

%	2
All ten studies of type 2 diabetes reported a reduction of HbA1c in participants using 
an app, with a median reduction of 0.55% (range 0.15% to 1.87%). After pooling the 
mean reduction in HbA1c was 0.49% (95% Cl 0.30%, to 0.68%; P < 0.001; 2=10%; 
Figure 3). These results exhibited consistent findings with no heterogeneity. One 
study reported a reduction larger than clinically anticipated which raised debate over 
the legitimacy of their findings (26).  After excluding the subgroup of studies that 
were assessed as poor quality, we found a mean reduction of 0.41% (95% CI 0.22%, 
to 0.61%; P<0.001; 2=0%; Figure 3). The level of evidence by GRADE was 
moderate, due to the findings being downgraded due to quality.  

)+$ %:)- 3  
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
The subgroup analysis by follow9up duration showed that five studies with a shorter 
follow9up duration (less than six months) displayed a larger (but non9significant) 
HbA1c reduction than those with a longer duration (greater than six months) 0.62% 
versus 0.40% (P = 0.33) respectively. There was no difference in the reduction of 
HbA1c in three studies with a mean diabetes duration of less than nine years 
(0.53%) compared to those with a duration ≥ 9 years (0.55%; P = 0.93).  Studies of 
younger participants with a mean age of ≤ 55 years reported a larger and clinically 
significant reduction in HbA1c level of 1.03% compared to those with an average age 
greater than 55 of 0.41%, but the result was not found to be statistically significant (P 
= 0.10). 
 
In the subgroup analysis by number of self9monitoring tasks six diabetes apps 
supported at most three self9monitoring tasks, and had similar results to those 
studies with more than three self9monitoring tasks (mean reduction of 0.44% versus 
0.58%; P = 0.56). Two studies of diabetes apps with only automated feedback had a 
small and statistically non9significant reduction in HbA1c of 0.26% (95% Cl 0.09%, to 
90.62%). When diabetes apps included HCP feedback were pooled, eight studies 
reported a reduction of 0.56% (95% Cl 0.35%, to 0.78%). There was no statistically 
significant difference between HCP verses automatic feedback subgroup (P = 0.16). 
 
Four sensitivity analyses were undertaken to test the robustness of the results. 
Removing three studies (20; 23; 26) with poor quality reported a mean reduction of 
0.41% (95% Cl 0.22%, to 0.61%, Figure 3). The removal of one study (17) with 
incomplete statistical information was associated with a mean reduction of 0.48% 
(95% CI 0.28%, to 0.67%), and the exclusion of one study (20) conducted on mixed 
participants with type 1 and type 2 diabetes had an attendant mean reduction of 
0.48% (95% Cl 0.27%, to 0.69%). Finally, the exclusion of two studies (17; 23) with 
baseline HbA1c levels > 9.0% was associated with a mean reduction of 0.47% (95% 
Cl 0.25%, to 0.69%).  

0
Ten studies were included for type 2 diabetes, predominately of fair quality. The 
results of these indicated a consistent reduction in HbA1c of 0.5%. Although there 
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was no indication of heterogeneity, the study conducted by Takenga et al. (26) 
introduced a large effect, that was likely to be caused by poor study quality (high 
attrition rate, differential loss to follow9up and high baseline HbA1c level). Thus, 
studies  were stratified into subgroup determined by their quality assessment (27). 
No differences were found between the subgroups, and the studies of poor quality 
were included for completeness, and to highlight the challenges in study design.  
 
Five subgroup analyses showed that the effect did not differ significantly by follow9up 
duration, mean diabetes duration of participants, mean age of participants, number 
of self9monitoring tasks supported by the diabetes apps, or types of feedback. 
Compared to studies that have investigated alternative interventions to improve their 
diabetes self9management, such as: text messaging, mobile device, computer based 
and convention self9management, we have found that apps offer promising results 
and reinforce the message argued by other authors (3; 4; 28930). The evidence for 
this finding by GRADE was moderate, after down grading due to quality.  
 
The subgroup analysis by follow9up duration suggested that the effect of diabetes 
apps on blood glucose control may attenuate over time. A possible rationale for this 
subgroup effect is a lack in user9friendliness, a lack in perceived additional benefits 
and a lack of use of gamification elements, resulting in a lack of efficacy following 
use (31). The subgroup analysis by mean age of participants indicated that younger 
patients were more likely to benefit from the use of the diabetes apps. It may be 
speculated that younger patients are more amenable to new technologies and more 
familiar with the use of mobile phones. The subgroup analysis by personalized 
feedback system highlighted the gap between automated feedback and healthcare 
professional feedback. Although automated feedback has the advantage of being 
interactive and dynamic, there is a limit to presupposed scenarios, whereas 
feedback provided by healthcare professionals was more individual, especially in 
emergency situations. Feedback options ranged widely between the apps, but it is 
postulated that it was the feedback that triggered improved lifestyle choices, which in 
turn lowered HbA1c. None of the five sensitivity analyses changed the overall effect 
size significantly, which suggests that the findings are not sensitive to these 
scenarios. The results of our meta9analysis lend support to the use of diabetes apps 
in diabetes self9management, especially for type 2 diabetes. However, we have 
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highlighted a number of limitations of current diabetes apps.  
 
For type 1 diabetes, there was little difference in HbA1c between intervention and 
control groups and the results were associated with considerable heterogeneity. The 
level of evidence by GRADE was downgraded to very low due to: study quality; 
inconsistency; and uncertainty; so the findings should be interpreted as very 
uncertain and likely to be change following future research. Furthermore, none of the 
apps in the included type 1 diabetes studies had an automatic data uploading 
functionality. In future studies for type 1 diabetes, we encourage investigators to 
include apps with this functionality, not only for the purpose of being user9friendly, but 
also for safety concerns by reducing the risk of data entry errors. 
 
Two studies reported on the cost effectiveness of the apps for type 1 diabetes with 
inconclusive findings (15; 16). Of three studies on type 2 diabetes that discussed 
compliance, two reported poor compliance with only 35% of patients regular app 
users (21; 24). One study (25) reported a decline in patient use over time, from 70% 
in the first week to 50% in the last two weeks. Four studies tried to explore the 
mechanisms behind the effects, but the conclusions were inconsistent (16; 17; 21; 
24). We postulate that diabetes apps influence lifestyle choice, but how this occurs is 
unclear. One hypothesis is that the reminder and feedback features of diabetes apps 
can lead to improvement in health beliefs, self9efficacy and social support (32).    
 
By the end of the decade, worldwide mobile phone usage is anticipated to exceed 5 
billion (33). Therefore apps may be able to offer an affordable and widely available 
adjunct to diabetes self9management. We have included studies across a variety of 
healthcare systems, from both the developed and developing world, so we argue the 
apps are currently available and could form the basis of improved health promotion 
on diabetes education and self9management. 
 
This study had several limitations. Since this review was restricted to published 
studies and so publication bias cannot be ruled out as highlighted by other 
investigators (30) All included study designs were not blinded, so were downgraded 
in the quality assessment tool, (highlighting the increased risk of ascertainment bias). 
Furthermore, patient9important outcomes and behavioral mechanisms and outcomes 
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were not considered and is a clear gap to be addressed in future studies. A further 
weakness is that some of the effect attributed to the apps could be explained by 
health care providers. Finally, there is no clear definition of diabetes apps and study 
authors defined their interventions in different ways as a result. In this review, we 
defined diabetes apps as software that is designed for use on a mobile phone 
allowing patients to enter data into the app and receive feedback. 
 
The implications for future research include establishing a common standardized 
platform of functionality.  Investigators of future studies need to consider adequately 
powered pragmatic RCTs with secure sequence generation, concealed allocation, 
use of an active control app, and comparable access to HCP. Features such as 
these might reduce the impact of ascertainment bias and effects due to HCP. RCTs 
with longer duration of follow up (> 6 months) using standardized app technology 
may well demonstrate beneficial clinical effect in type 2 diabetes. Furthermore, there 
is significant scope for research in the use of apps in other areas of self9
management, such as increasing physical activity, weight loss and smoking 
cessation. 
 
In a clinical context, we recommend that HCP feedback should be central in all future 
app design and supplemented with dynamic automated feedback. Future technology 
should also be underpinned by behavior change theories and gamification elements 
to achieve a larger effect on blood glucose control and improve compliance of 
patients in using diabetes apps. Finally, future technology should also consider the 
needs of older patients.  
 
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#$%&%

'#( &%)* $To investigate the effect of mobile phone applications on glycemic 
control (HbA1c) in the self 9management of diabetes. 
 $ & $)++, %'$Relevant studies that were published 
between 1996 to June 1st, 2015 were searched from five databases: Medline, 
CINAHL, The Cochrane Library, Web of Science, and EMBASE. Randomized 
controlled trials that evaluated diabetes apps were included. We conducted a 
systematic review with meta9analysis and GRADE of the evidence. 
 $-.%$1360 participants from 14 studies were included and quality assessed. 
Whilst there may have been clinical diversity, all type 2 diabetes studies reported a 
reduction in HbA1c. The mean reduction in participants using an app compared to 
control was 0.49% (95% Cl 0.30%90.68%;=10%), with a moderate GRADE of 
evidence. Subgroup analyses indicated that younger patients were more likely to 
benefit from the use of diabetes apps and the effect size was enhanced with 
healthcare professional feedback. There was inadequate data to describe the 
effectiveness of apps for type 1 diabetes. 
&'+&.-$)'+$Apps may be an effective component to help control HbA1c, and 
could be considered as an adjuvant intervention to the standard self9management for 
patients with type 2 diabetes. Given the reported clinical effect, and the access and 
nominal cost of this technology, it is likely to be cost9effective at the population level. 
The functionality and use of this technology needs to be standardized, but policy and 
guidance is anticipated to improve diabetes self9management care and reduce 
healthcare cost. 

/&01234
/&0,0	13552
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 There is a moderate level of evidence that the self9management of type 2 
diabetes is improved by using smart phone applications to reduce HbA1c 
 
 Apps for type 2 diabetes may offer a clinically effective adjuvant component to 
in the self9medicationmanagement of type 2 diabetes 
 
 Younger users were associated with the largest reduction in HbA1c 
 
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The number of diabetes patients globally is expected to rise to over 500 million by 
2030 (1), there is an urgent need for an improved self9management suite of 
interventions. For self9management to be effective it needs to be structured and cost 
effective (2), and be widely accessible across all health economies, including the 
developing world (2). 
As a newly emerging technology, diabetes mobile phone applications (hereafter 
referred to as diabetes apps) are a promising tool for self9management. We define 
diabetes apps as mobile phone software that accepts data (transmitted or manual 
entry), and provides feedback to patients on improved management (automated or 
by health care profession [HCP]). This technology combines the functions of the 
mobile phone, wireless network for data transmission and sometimes HCPs for 
providing feedback. Due to its ubiquitous, low cost, interactive, and  dynamic health 
promotion, there is potential for diabetes apps to provide an cost9effective 
intervention in diabetes self9care. 
In terms of diabetes self9management, numerous studies have proven the 
effectiveness of other telemedicine technologies, such as short message service (3), 
computer9based interventions (4), and web9based interventions (3; 5). Compared 
with these telemedicine interventions, diabetes apps are advantageous in that they 
are global, cheaper, convenient, and more interactive. There is however, current 
uncertainty on the clinical effectiveness of diabetes apps in diabetes self9
management (699).  
 
, %'$
 
0

The PRISMA statement and checklist was followed. Five electronic databases were 
searched (Medline, CINAHL, The Cochrane Library, Web of Science, and EMBASE) 
for studies published between January 1st, 1996 to  June 1st, 2015. Included studies’ 
references were hand searched to identify any additional articles. The following 
terms and medical subject headings (MeSH) were used during the search: (mobile 
OR mHealth OR cell phone OR MeSH “Cellular Phone” OR MeSH “Smartphone” OR 
app OR MeSH “Mobile Applications”) AND (MeSH “Diabetes Mellitus” OR diabete* 
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OR T2DM OR T1DM OR IDDM OR NIDDM).  
 
)070
The inclusion criteria were: the participants were over 18 years old and had type 1 or 
type 2 diabetes; the studies were randomized controlled trials (RCTs); the control 
group in the study received usual diabetes care without any telehealth programs; 
baseline and follow9up mean for HbA1c were reported (or could be calculated).; 
Exclusion criteria were: simulated or self9reported HbA1c data; computer or other 
mobile terminal9based diabetes apps; diabetes apps were exclusively designed for 
HCPs; and diabetes apps were exclusively designed for providing general education, 
or allowing communication between patients and HCPs.  
 
Two reviewers (CH, TF) searched the literature and assessed the studies 
independently. Any disagreements were resolved through discussion with a third 
reviewer (BC). No language restrictions were applied.  
 
7 
Participant demographics, study design considerations and context were extracted 
from the included studies. Two reviewers independently carried out the data 
extraction (CH, TF). Study authors were contacted to provide additional data, and 
missing standard deviations were estimated by calculation (10). 
 
80 
The quality assessment was conducted by two reviewers independently (CH, TF), 
using the quality rating tool proposed by the US Preventive Service Task Force (11).  
Seven criteria were used to assess quality: baseline comparability of the groups; the 
maintenance of comparability of the groups; differential or high loss to follow9up; 
reliable  and valid measurement; clear definition of the intervention; consideration of 
important outcomes; and an intention9to9treat analysis. The quality of each study was 
graded as Good, Fair, or Poor. To be rated as good studies needed to meet all the 
criteria. A study with a fair quality had to be free of fatal flaws and a study with at 
least one fatal flaw was recorded as having a poor quality.A study was rated as poor 
if one (or more) domain was assessed as having a serious flaw. Studies that met 
some but not all of the criteria was rated as fair quality.  
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
Changes in HbA1c, or HbA1c at follow9up were compared between groups using a 
mean difference, and were presented with an associated 95% confidence interval 
(95% CI). When studies investigated interventions and contexts that were both 
deemed clinically similar, and free from statistical heterogeneity, pooling was carried 
using an inverse variance random effects model (12). Meta9analyses were 
conducted using the Comprehensive Meta9Analysis Software (version 2.2). The level 
of evidence was applied to the GRADE criteria and reported. 
 
00	
Heterogeneity was assessed and quantified using the  statistic. When substantial 
heterogeneity was found (2>50%), further exploration using subgroup analysis was 
undertaken. For type 2 diabetes studies, subgroup analyses were: follow9up duration 
(less than six months, versus more than six months); length of time with diabetes 
(less than nine years, versus more than nine years); age of participants (mean age 
less than 55 years old, versus more than 55 years old); number of self9monitoring 
tasks supported by the diabetes apps (up to three, versus greater than three); and 
types of feedback provided. No type 1 diabetes subgroup analyses were performed 
due to the small number of studies.  
 
$	0 
Additional analyses were carried out on studies with: good or fair quality; complete 
information; and studies with a baseline HbA1c level less than 9.0%. A funnel plot 
was used to visually inspect publication bias where 10 or more studies were pooled.  
 
0
)00
Searches identified 5209 articles (Figure 1), 4238 were screened after removing 
duplicate records and 4178 were excluded. Sixty studies were eligible for full text 
review and 42 were excluded (Figure 1) resulting in 14 included studies. Four studies 
examined type 1 diabetes and 10 studies examined type 2 diabetes. 

&

0090
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In the 14 studies, there were 1360 participants, 509 and 851 with type 1 and type 2 
diabetes respectively (Online Table 1). In the type 1 diabetes studies, the mean age 
of participants ranged from 34 (13) to 36 years old (14), and the mean duration of 
diabetes ranged from 16 (13915) to 19 years (16). Two studies were undertaken in 
Europe (13; 14), one in Australia (16) and one was multinational (15). In the type 2 
diabetes studies, the mean age of the participants was much higher, ranging from 51 
(17) to 62 years old (18) and the mean duration of diabetes ranged from five (19) to 
13 years (20) from six studies. Four studies were undertaken in Europe (18; 20922), 
three in the USA (17; 23; 24), two in Asia (19; 25) and one in Africa (26).  
 
Our quality assessment of theOne type 1 diabetes study was assessedies report one  
rated as good quality (14), two were rated as fair (13; 15), and one was rated as poor 
(16), for further details see Online Table 2. For type 2 diabetes studies, one was 
rated as good quality (21), six were rated as fair (17919; 22; 24; 25) and three were 
rated as poor (20; 23; 26) (Online Table 2). 

)+&.- :)-   
		0
00
Twelve diabetes apps were identified and examined in this review, with six domains 
of functionality (Online Table 3), details of the feedback provided by each can be 
seen in Online Table 4 
 
%			
Three apps were used for participants with type 1 diabetes and aimed to help 
patients to calculate the most appropriate insulin bolus, on the basis of patient blood 
glucose levels, food intake and physical activity. Data for all three apps were 
manually entered. One study reported that there was little impact of the app on the 
total time spent on face9to9face or telephone follow9up and concluded that the 
software did not require more time for patients to manage their diabetes (13). A 
further study estimated the average cost to patients and educators time was £38 per 
patient, attributed to the app over a 9 month period (16). HCP feedback was 
provided in all apps, with a frequency ranging from every week to every three weeks 
(Online Table 4). 
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%	2		
Nine apps were used for participants with type 2 diabetes. The apps were designed 
to improve patient self9management, by providing personalized feedback on self9
monitoring data, such as blood glucose, food intake, and physical activity. In eight of 
the apps, BG was automatically transferred and other data manually entered., with 
one exception where BP, body weight and pedometer was also automatically 
transferred (25),.Quinn et al. (17) reported that the app was associated with shorter 
consultation times. Among seven apps with HCP feedback, three provided feedback 
when needed (eg patient data were considered abnormal). In the remaining other 
apps, the frequency of feedback ranged from once a week to once every three 
months (Online Table 4).

 
		
%	
There were mixed results forom the type 1 diabetes studies. Two studies (14; 15) 
found no difference between the intervention group and the control group and two 
studies (13; 16) reported statistically significant results that favored the apps . There 
was a statistically insignificant difference in HbA1c between the apps and control 
group of 90.36% (95% Cl 90.87% to 0.14%, P = 0.16,  = 87%; Figure 2). No 
subgroup analyses were reported.  
 
)+&.- :)- 2  

%	2
All ten studies of type 2 diabetes reported a reduction of HbA1c in participants using 
an app, with aand the median reduction from the studies wasof 0.55% (range 0.15% 
to 1.87%). After pooling the mean reduction in HbA1c was 0.49% (95% Cl 0.30%, to 
0.68%; P < 0.001; 2=10%; Figure 3). These results exhibited consistent findings with 
no heterogeneity. One study reported results a reduction larger than clinically 
anticipated which raised debate over the legitimacy of their findings (26).  After 
excluding the subgroup of studies that were quality assessed as poor qualityand only 
including those studies with good or fair quality, we found a mean reduction of 0.41% 
(95% CI 0.22%, to 0.61%; P<0.001; 2=0%; Figure 3). The level of evidence by 
GRADE was moderate, due to the findings being downgraded due to quality.  
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%	200	
The subgroup analysis by follow9up duration showed that five studies with a shorter 
follow9up duration (less than six months) displayed a larger (but non9significant) 
HbA1c reduction than those with a longer duration (greater than six months) 0.62% 
versus 0.40% (P = 0.33) respectively. There was no difference in the reduction of 
HbA1c in three studies with a mean diabetes duration of less than nine years 
(0.53%) compared to those with a duration ≥ 9 years (0.55%; P = 0.93).  Studies of 
younger participants with a mean age of ≤ 55 years reported a larger and clinically 
significant reduction in HbA1c level of 1.03% compared to those with an average age 
greater than 55 of 0.41%, but the result was not found to be statistically significant (P 
= 0.10). 
 
The In the subgroup analysis by number of self9monitoring tasks found no difference. 
S six diabetes apps that supported at most three self9monitoring tasks, and had 
similar results to those studies with more than three self9monitoring tasks (mean 
reduction of 0.44% versus 0.58%; ,P = 0.56). Two studies of diabetes apps with only 
automated feedback had a small and statistically non9significant reduction in HbA1c 
of 0.26% (95% Cl 0.09%, to 90.62%). When diabetes apps included HCP feedback 
wereas pooled, eight studies reported a reduction of 0.56% (95% Cl 0.35%, to 
0.78%). There was no statistically significant difference between HCP verses 
automatic feedback subgroup (P = 0.16). 
 
Four sensitivity analyses were undertaken to test the robustness of the results. 
Removing three studies (20; 23; 26) with poor quality reported a mean reduction of 
0.41% (95% Cl 0.22%, to 0.61%, Figure 3). The removal of one study (17) with 
incomplete statistical information was associated with a mean reduction of 0.48% 
(95% CI 0.28%, to 0.67%), and the exclusion of one study (20) conducted on mixed 
participants with type 1 and type 2 diabetes had an attendant mean reduction of 
0.48% (95% Cl 0.27%, to 0.69%). Finally, the exclusion of two studies (17; 23) with 
baseline HbA1c levels > 9.0% was associated with a mean reduction of 0.47% (95% 
Cl 0.25%, to 0.69%).  
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
Ten studies were included for type 2 diabetes, of predominately of fair quality. The 
results of these indicated a consistent reduction in HbA1c of 0.5%. Although there 
was no indication of heterogeneity, the study conducted by Takenga et al. (26) 
introduced a large effect, that was likely to be caused by poor study quality (high 
attrition rate, differential loss to follow9up and high baseline HbA1c level). Subgroup 
of study quality were used to stratify studies with a poor quality assessment, 
compared to those with a fair and good quality assessment Thus, studies  were 
stratified into subgroup determined by their quality assessment (27). No differences 
were found between the subgroups based on quality, and the studies of poor quality 
were included for completeness, and to highlight the challenges in study design.  
 
Five subgroup analyses showed that the effect did not differ significantly by follow9up 
duration, mean diabetes duration of participants, mean age of participants, number 
of self9monitoring tasks supported by the diabetes apps, or types of feedback. 
Compared to studies that have investigated alternative interventions to improve their 
diabetes self9management of HbA1c, such as: text messaging, mobile device, 
computer based and convention self9management, we have found that apps offer 
promising results and reinforce the message argued by other authors (3; 4; 28930). 
The evidence for this finding by GRADE was moderate, after down grading due to 
quality.  
 
The subgroup analysis by follow9up duration suggested that the effect of diabetes 
apps on blood glucose control may attenuate over time. A possible rationale for this 
subgroup effect is a lack in user9friendliness, a lack in perceived additional benefits 
and a lack of use of gamification elements, resulting in a lack of efficacy following 
use (31). The subgroup analysis by mean age of participants indicated that younger 
patients were more likely to benefit from the use of the diabetes apps. It may be 
speculated that younger patients are more amenable to new technologies and more 
familiar with the use of mobile phones. The subgroup analysis by personalized 
feedback system highlighted the gap between automated feedback and healthcare 
professional feedback. Although automated feedback has the advantage of being 
interactive and dynamic (and probably cost9effective), there is a limit to presupposed 
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scenarios, whereas feedback provided by healthcare professionals wais more 
individual, especially in emergency situations. Feedback options ranged widely 
between the apps, but it is postulated that it was the feedback that triggered 
improved lifestyle choices, which in turn lowered HbA1c. None of the five sensitivity 
analyses changed the overall effect size significantly, which suggests that the 
findings are not sensitive to these scenarios. The results of our meta9analysis lend 
support to the use of diabetes apps in diabetes self9management, especially for type 
2 diabetes. However,  we have highlighted a number of limitations of current 
diabetes apps.  
 
For type 1 diabetes, there was little difference in HbA1c between intervention and 
control groups and the results were associated with considerable heterogeneity. The 
level of evidence by GRADE was downgraded to very low  due to: study quality; 
inconsistency; and uncertainty; so the findings should be interpreted as very 
uncertain and likely to be change following future research. Furthermore, none of the 
apps in the included type 1 diabetes studies had an automatic data uploading 
functionality. In future studies for type 1 diabetes, we encourage investigators to 
include apps with this functionality, not only for the purpose of being user9friendly, but 
also for safety concerns by reducing the risk of data entry errors. 
 
Two studies reported on the cost effectiveness of the apps for type 1 diabetes with 
inconclusive findings (15; 16) on type 1 diabetes reported on the cost of the 
intervention. Although the data provided by the two studies seemed to favor the 
diabetes apps as a low9cost self9management intervention for type 1 diabetes, its 
effect on diabetes self9management is still questioned. Of tThree studies on type 2 
diabetes that discussed compliance,described patient compliance, and  two reported 
poor compliance of the patients, reporting compliance with only 35% of patients as 
regular app users (21; 24). One study (25) reported a decline in patient use over 
time, from 70% in the first week to 50% in the last two weeks. Four studies tried to 
explore the mechanisms behind the effects, but the conclusions were inconsistent 
(16; 17; 21; 24). We postulate that diabetes apps influence lifestyle choice, but how 
this occurs is unclear. One hypothesis is that the reminder and feedback features of 
diabetes apps can lead to improvement in health beliefs, self9efficacy and social 
support (32).    
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By the end of the decade, worldwide mobile phone usage is anticipated to exceed 5 
billion (33). Therefore apps may be able to offer an affordable and widely available 
adjunct to diabetes self9management. We have included studies across a variety of 
healthcare systems, from both the developed and developing world, so we argue the 
apps are currently available and could form the basis of improved health promotion 
on diabetes education and self9management. 
 
This study had several limitations. Since this review was restricted to published 
studies and so publication bias cannot be ruled out as highlighted by other 
investigators (30) All included study designs were unblindednot blinded, so were 
downgraded in the quality assessment tool, (highlighting the increased risk of 
ascertainment bias). Furthermore, patient9important outcomes and behavioral 
mechanisms and outcomes were not considered and is a clear gap to be addressed 
in future studies. A further weakness is that some of the effect attributed to the apps 
could be explained by health care providers. Finally, there is no clear definition of 
diabetes apps and study authors defined their interventions in different ways as a 
result. In this review, we defined diabetes apps as software that is designed for use 
on a mobile phone allowing patients to enter data into the app, with response to the 
inputted data through either automatically generated feedback or patients’ HCPs’ 
feedback. and receive feedback. 
 
The implications for future research include establishing a common standardized 
platform of functionality.  Investigators of future studies need to consider adequately 
powered pragmatic RCTs with secure sequence generation, concealed allocation, 
use of an active control app, and comparable access to HCP. Features such as 
these might reduce the impact of ascertainment bias and effects due to HCP. RCTs 
with longer duration of follow up (> 6 months) using standardized app technology 
may well demonstrate beneficial clinical effect in type 2 diabetes. Furthermore, there 
is significant scope for research in the use of apps in other areas of self9
management, such as increasing physical activity, weight loss and smoking 
cessation. 
 
In a clinical context, the need to consider patient safety issues is of paramount 
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importance with apps aligned with current diabetes self9management guidelines. 
Wwe recommend that HCP feedback should be central in all future app design and 
supplemented with dynamic automated feedback. Future technology should also be 
underpinned by behavior change theories and gamification elements to achieve a 
larger effect on blood glucose control and improve compliance of patients in using 
diabetes apps. Finally, future technology should also consider the needs of older 
patients.  
 
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